OPDUALAG
(Opdualag)Phase 2Small molecule
Bristol-Myers SquibbOPDUALAG is one of 84 small molecule programs targeting Melanoma. It is currently in Phase 2.
3
Indications
3
Total Trials
3
Active Trials
83
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Cotellic
RochePhase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Libtayo
RegeneronPhase 3
Intron a
Merck & Co.Phase 3
Opdualag
Bristol-Myers SquibbPhase 3
Fabhalta
RegeneronPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Locally Advanced or Metastatic Solid Tumors1 trial
Melanoma1 trial
Adolescent1 trial
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Recruiting·AAustralian & New Zealand Children's Haematology/Oncology Group·Phase 1/2·NCT06208657·90 enrolled
Regulatory
FDA Approval Timeline[4]
Mar 18, 2022
OPDUALAG
BLA BLA761234
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Opdualag. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company